Trikafta "27 more years at full health" claim.

Laydan Mortensen made this Official Information request to Pharmaceutical Management Agency

Currently waiting for a response from Pharmaceutical Management Agency, they must respond promptly and normally no later than (details and exceptions).

From: Laydan Mortensen

Dear Pharmaceutical Management Agency,

On 15 August 2022, Pharmac made a press release (https://pharmac.govt.nz/news-and-resourc...) on the funding application for Trikafta (elexacaftor/texacaftor/ivacaftor) stating: "We also estimate that Trikafta could give people with cystic fibrosis who are aged 6 and over a longer and improved quality of life – specifically benefits equivalent to 27 more years at full health when compared to current funded treatments." The "27 more years at full health" figure has been widely publicised by advocacy groups and the media, but I can't seem to find a source or any form of calculation on how that figure was obtained. The closest I got was from the publicly-available technology assessment report, which show an incremental QALY gain of 9.8 years, just a third of the stated 27 years.

Can you please release information of how the "27 more years at full health" figure was calcuated?

Yours faithfully,

Laydan Mortensen

Link to this

From: Web Enquiry
Pharmaceutical Management Agency

Kia ora Laydan

Thank you for your request for official information, which Pharmac received on 17 January 2025. The reference number for your request is: 2024-25-101

You should receive a response from us on or before 17 February 2025. This is within the 20 working day limit set out in the Official Information Act.

Please contact us if you have any questions.

Ngâ mihi,

Government Services | Pharmac
___________________________________________________________________
Pharmac - Te Pâtaka Whaioranga | Level 9, 40 Mercer Street, Wellington
http://www.pharmac.govt.nz/

-----Original Message-----
From: Laydan Mortensen <[FOI #29777 email]>
Sent: Friday, January 17, 2025 9:25 AM
To: Web Enquiry <[email address]>
Subject: Official Information request - Trikafta "27 more years at full health" claim.

[You don't often get email from [FOI #29777 email]. Learn why this is important at https://aka.ms/LearnAboutSenderIdentific... ]

Dear Pharmaceutical Management Agency,

On 15 August 2022, Pharmac made a press release (https://pharmac.govt.nz/news-and-resourc...) on the funding application for Trikafta (elexacaftor/texacaftor/ivacaftor) stating: "We also estimate that Trikafta could give people with cystic fibrosis who are aged 6 and over a longer and improved quality of life – specifically benefits equivalent to 27 more years at full health when compared to current funded treatments." The "27 more years at full health" figure has been widely publicised by advocacy groups and the media, but I can't seem to find a source or any form of calculation on how that figure was obtained. The closest I got was from the publicly-available technology assessment report, which show an incremental QALY gain of 9.8 years, just a third of the stated 27 years.

Can you please release information of how the "27 more years at full health" figure was calcuated?

Yours faithfully,

Laydan Mortensen

-------------------------------------------------------------------

This is an Official Information request made via the FYI website.

Please use this email address for all replies to this request:
[FOI #29777 email]

Is [PHARMAC request email] the wrong address for Official Information requests to Pharmaceutical Management Agency? If so, please contact us using this form:
https://fyi.org.nz/change_request/new?bo...

Disclaimer: This message and any reply that you make will be published on the internet. Our privacy and copyright policies:
https://fyi.org.nz/help/officers

If you find this service useful as an Official Information officer, please ask your web manager to link to us from your organisation's OIA or LGOIMA page.

-------------------------------------------------------------------

This e-mail message and any accompanying attachments may contain confidential information. If you are not the intended recipient, please do not read, use, disseminate, distribute or copy this message or attachments. If you have received this message in error, please notify the sender immediately and delete this message.

hide quoted sections

Link to this

Things to do with this request

Anyone:
Pharmaceutical Management Agency only: